Tags Archive Navigation
icon
-
Media ReleaseNew Zolgensma data demonstrate age-appropriate development when used early, real-world benefit in older children and durability 5+ years post-treatment
-
Media ReleaseNovartis signs initial agreement to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient for Roche’s Actemra/RoActemra®
-
Media ReleaseNovartis announces winners of the Innovation Prize for Assistive Tech, rewarding new technologies that could improve mobility and independence of people living with multiple sclerosis
-
Media ReleaseNovartis announces ambitious ESG targets to increase access to medicines and achieve full carbon neutrality